Thrivent Financial for Lutherans
RUBY

Thrivent Financial for Lutherans’s Rubius Therapeutics, Inc RUBY Stock Holding History

Thrivent Financial for Lutherans’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-40,782
Closed -$730K – 2519
2021
Q3 		$730K Buy
40,782
+25,895
+174% +$563K ﹤0.01% 2005
2021
Q2 		$363K Buy
+14,887
New +$372K ﹤0.01% 2281

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Thrivent Financial for Lutherans's RUBY Position: Q4 2021 in Review

Thrivent Financial for Lutherans sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2021, closing a stake of 40,782 shares — an estimated $730K sold.

Thrivent Financial for Lutherans first reported a position in RUBY in Q2 2021 and held it in 2 quarters. The position peaked at $730K in Q3 2021. 108 funds tracked by Wall St. Rank hold RUBY as of Q4 2021.

  • Thrivent Financial for Lutherans reported no remaining Rubius Therapeutics, Inc position as of Q4 2021 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 40,782 Rubius Therapeutics, Inc shares in Q4 2021, an estimated $730K.
  • Thrivent Financial for Lutherans first reported a position in Rubius Therapeutics, Inc in Q2 2021 and held it in 2 quarters.
  • Thrivent Financial for Lutherans's Rubius Therapeutics, Inc position peaked at $730K in Q3 2021.
  • 108 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2021.

Based on Thrivent Financial for Lutherans's 13F filing for Q4 2021, filed 16 Feb 2022.